October 2025

Early clinical trial results show that AlphaMedix™ (212Pb-DOTAMTATE), an investigational targeted alpha therapy, achieved all of its main goals and produced clinically meaningful benefits for adults with advanced gastroenteropancreatic neuroendocrine tumors (GEP-NETs).

The therapy showed positive results both in patients who had never received peptide receptor radionuclide therapy (PRRT) and in those whose cancer had returned or progressed after prior PRRT. Read more. 

Chimeric Therapeutics has reported that a neuroendocrine cancer patient in the Phase 1 clinical trial of CAR T cell therapy has experienced tumor shrinkage. In an update for investors on October 8, Chimeric reported 8 patients have been treated so far, with two more awaiting treatment. Read more. 

A phase I CAR T-cell clinical trial targeting the molecule IL13Rα2 found on the surface of some tumors began at the University of California, Los Angeles (UCLA) last year and has now expanded to City of Hope and Stanford University. Learn more about trial details and eligibility.  Read more. 

The early results from a first-in-human clinical trial suggest that a novel copper-based PET imaging agent may deliver clearer and more comprehensive scans for people living with neuroendocrine tumors (NETs).  Read more.

The Education and Research Foundation for Nuclear Medicine and Molecular Imaging (ERF) in partnership with NETRF is proud to announce Dr. Carolin Kitzberger of TUM University Hospital Rechts der Isar as the 2025 recipient of the Nuclear Medicine Pilot Research Grant in Neuroendocrine Tumors (NETs). The award recognizes Dr. Kitzberger’s innovative approach to advancing NET treatment and diagnosis through cutting-edge molecular imaging and cellular therapy. Read more. 

A 2020 NETRF-funded study, led by Patricia Dahia, MD, PhD (UT Health San Antonio) and Alice Soragni, PhD (UCLA), uncovers how oxygen levels shape tumor behavior and expose new treatment opportunities for pheochromocytomas and paragangliomas. Read more.

Neuroendocrine cancers, such as neuroendocrine tumors (NETs) and neuroendocrine carcinomas (NECs), are uncommon and complex. That makes every patient sample incredibly valuable, whether it’s a biopsy, tissue from surgery, or a tube of blood. With the right handling and planning, one sample can fuel many discoveries: from new drug targets to better tests that spare future patients extra procedures. Read more. 

In his self-produced mini documentary, "The Healing Garden," Jake Dawson shares a very personal story of renewal, resilience, and hope.

Thanks to Jake for sharing this film and for his ongoing support for NETRF. 

Watch Jake's story

This month’s Thrivership video focuses on strengthening our resilience muscles, those inner tools that help us bend without breaking when life throws the unexpected our way. We’ll explore a few new ways to help you stay grounded, flexible, and confident as you navigate uncertainty and growth.

We’ve refreshed the NETWise podcast page on our website to make it easier than ever to find the stories and insights that matter most to you.

Episodes are now organized into curated collections by topic. Whether you’re seeking information about diagnosis, treatment, living well day-to-day, or caregiver support, you can quickly find the conversations that fit your journey.

Explore the updated page today and don’t forget to subscribe so you won’t miss an episode.

This fall, you can make an impact by supporting two wonderful events benefiting NETRF. Attend in person, participate online, or reach out if you’d like to host an event of your own. Every effort helps advance research and hope for the neuroendocrine cancer community.

Celebration for Sheryl
Hosted by Jim Jungsten
Saturday, November 1, 2025
North Ridge Country Club, Fair Oaks, CA
Everyone is invited to participate in the event's online silent auction, open now through October 31. Featuring luxurious hotel stays across the country, the auction's proceeds benefit NETRF.

effNETs Fundraiser (Golf Tournament and Reception)
Hosted by Chris & Jessica Ochoa
Friday, November 21, 2025
Stoneybrook West Golf Course, Winter Garden, FL

Whether it’s a walk, golf outing, bake sale, or online fundraiser, every community event helps fuel research and hope. Contact us to learn how we can help you bring your idea to life! Email Steve Perna at steve.perna@netrf.org for more information. 

On a beautiful fall day at Knob Hill Golf Course in Manalapan Township, NJ, loved ones came together for the First Annual Frank DeBenedetto Golf Outing to benefit NETRF.

The event was a heartfelt tribute to Frank DeBenedetto, a devoted husband, father, and retired NYPD Lieutenant, whose life of service and compassion continues to inspire all who knew him.

Through a day filled with camaraderie and generosity, the outing raised $10,000 to advance neuroendocrine cancer research.

A special thank you to Marie and Gina DeBenedetto and the many friends and family members who made this day such a meaningful celebration of Frank’s life and legacy. 

We’re honored to partner with Citizens of Humanity, a company that gives back in a beautiful way — to celebrate the life and legacy of Lindsay May Palevsky through the Lindz jean. For every pair sold, $50 supports NETRF. Endorsed by style icons Simone Harouche and Kim Kardashian, the Lindz jean honors Lindsay's spirit of love, generosity, and purpose. Get yours before year's end or while supplies last.

Shop the Lindz

NETRF is excited to announce that Anna Greene, PhD has been promoted to Chief Scientific Officer. Dr. Greene joined NETRF in 2023 as Director of Research. Anna has been a strategic leader, helping to shape the next phase of NETRF’s research strategy and success. Dr. Greene has developed our Research Roadmap, expanded the annual NETRF Research Symposium, and collaborated with the Board of Scientific Advisors to increase the effectiveness of NETRF’s grantmaking process.

In her new role, she will continue to bring scientific insight and passion to our mission: funding innovative neuroendocrine cancer research around the world, supporting the NET/NEC research community, and forging meaningful collaborations.

“Anna has become a trusted partner to the staff, as well as to the NETRF Board of Scientific Advisors and Board of Directors,” says Elyse Gellerman, CEO. “We look forward to her continued leadership as we ensure that NETRF accelerates scientific discovery and development of new treatments.”

NET Research Foundation
100 Hancock Street,
Third floor
Quincy, MA 02171
(617) 946-1780 info@netrf.org

The mission of the Neuroendocrine Tumor Research Foundation is to fund research to discover cures and more effective treatments for neuroendocrine cancer. NETRF is the largest global funder of neuroendocrine research and a preeminent resource for expert patient education and support.



NETRF is a 501(c)(3) organization. All donations are tax-deductible to the extent allowed by law.